Interindividual variability in the prevalence of OPRM1 and CYP2B6 gene variations may identify drug-susceptible populations
Authors: Bunten, H., Liang, W.J., Pounder, D.J., Seneviratne, C. and Osselton, D.
Journal: Journal of Analytical Toxicology
Volume: 35
Issue: 7
Pages: 431-437
eISSN: 1945-2403
ISSN: 0146-4760
DOI: 10.1093/anatox/35.7.431
Abstract:Methadone is used worldwide for the treatment of heroin addiction; however, fatal poisonings are increasingly reported. The prevalence of CYP2B6 and μ-opioid receptor (OPRM1) gene variations were examined between a postmortem population where the deaths were associated with methadone and a live nondrug-using control population using Taqman™ SNP Genotyping assays. The CYP2B6*6 allele was higher in the postmortem population, but the difference was not significant (P = 0.92). The CYP2B6 T750C promoter variation was similar in frequency for both populations. Linkage between T750C and CYP2B6*6 was identified for both populations (P < 0.01). The prevalence of the OPRM1 A118G variation was significantly higher in the control population (P = 0.0046), which might indicate a protective mechanism against opioid toxicity. Individual susceptibility to methadone may be determined by screening for CYP2B6*6.
https://eprints.bournemouth.ac.uk/18477/
Source: Scopus
Interindividual variability in the prevalence of OPRM1 and CYP2B6 gene variations may identify drug-susceptible populations.
Authors: Bunten, H., Liang, W.J., Pounder, D.J., Seneviratne, C. and Osselton, D.
Journal: J Anal Toxicol
Volume: 35
Issue: 7
Pages: 431-437
eISSN: 1945-2403
DOI: 10.1093/anatox/35.7.431
Abstract:Methadone is used worldwide for the treatment of heroin addiction; however, fatal poisonings are increasingly reported. The prevalence of CYP2B6 and μ-opioid receptor (OPRM1) gene variations were examined between a postmortem population where the deaths were associated with methadone and a live nondrug-using control population using Taqman™ SNP Genotyping assays. The CYP2B6*6 allele was higher in the postmortem population, but the difference was not significant (P = 0.92). The CYP2B6 T750C promoter variation was similar in frequency for both populations. Linkage between T750C and CYP2B6*6 was identified for both populations (P < 0.01). The prevalence of the OPRM1 A118G variation was significantly higher in the control population (P = 0.0046), which might indicate a protective mechanism against opioid toxicity. Individual susceptibility to methadone may be determined by screening for CYP2B6*6.
https://eprints.bournemouth.ac.uk/18477/
Source: PubMed
Interindividual Variability in the Prevalence of <i>OPRM1</i> and <i>CYP2B6</i> Gene Variations May Identify Drug-Susceptible Populations
Authors: Bunten, H., Liang, W.J., Pounder, D.J., Seneviratne, C. and Osselton, D.
Journal: JOURNAL OF ANALYTICAL TOXICOLOGY
Volume: 35
Issue: 7
Pages: 431-437
eISSN: 1945-2403
ISSN: 0146-4760
DOI: 10.1093/anatox/35.7.431
https://eprints.bournemouth.ac.uk/18477/
Source: Web of Science (Lite)
Interindividual variability in the prevalence of OPRM1 and CYP2B6 gene variations may identify drug-susceptible populations
Authors: Bunten, H., Liang, W.-J., Pounder, D. and Osselton, D.M.
Journal: Journal of Analytical Toxicology
Volume: 35
Pages: 431-437
https://eprints.bournemouth.ac.uk/18477/
Source: Manual
Preferred by: Wei-Jun Liang and David Osselton
Interindividual variability in the prevalence of OPRM1 and CYP2B6 gene variations may identify drug-susceptible populations.
Authors: Bunten, H., Liang, W.J., Pounder, D.J., Seneviratne, C. and Osselton, D.
Journal: Journal of analytical toxicology
Volume: 35
Issue: 7
Pages: 431-437
eISSN: 1945-2403
ISSN: 0146-4760
DOI: 10.1093/anatox/35.7.431
Abstract:Methadone is used worldwide for the treatment of heroin addiction; however, fatal poisonings are increasingly reported. The prevalence of CYP2B6 and μ-opioid receptor (OPRM1) gene variations were examined between a postmortem population where the deaths were associated with methadone and a live nondrug-using control population using Taqman™ SNP Genotyping assays. The CYP2B6*6 allele was higher in the postmortem population, but the difference was not significant (P = 0.92). The CYP2B6 T750C promoter variation was similar in frequency for both populations. Linkage between T750C and CYP2B6*6 was identified for both populations (P < 0.01). The prevalence of the OPRM1 A118G variation was significantly higher in the control population (P = 0.0046), which might indicate a protective mechanism against opioid toxicity. Individual susceptibility to methadone may be determined by screening for CYP2B6*6.
https://eprints.bournemouth.ac.uk/18477/
Source: Europe PubMed Central
Interindividual variability in the prevalence of OPRM1 and CYP2B6 gene variations may identify drug-susceptible populations
Authors: Bunten, H., Liang, W.-J., Pounder, D. and Osselton, D.M.
Journal: Journal of Analytical Toxicology
Volume: 35
Pages: 431-437
https://eprints.bournemouth.ac.uk/18477/
Source: BURO EPrints